Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.

Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Jul 10;6(19):17147-60.

2.

Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus.

Tornese G, Tisato V, Monasta L, Vecchi Brumatti L, Zauli G, Secchiero P.

Acta Diabetol. 2015 Apr 12. [Epub ahead of print] No abstract available.

PMID:
25863780
3.

TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.

Perri P, Zauli G, Gonelli A, Milani D, Celeghini C, Lamberti G, Secchiero P.

Biomed Res Int. 2015;2015:424019. doi: 10.1155/2015/424019. Epub 2015 Mar 5. Review.

4.

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.

Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Mar 30;6(9):6597-610.

5.

TRAIL modulates the immune system and protects against the development of diabetes.

Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B.

J Immunol Res. 2015;2015:680749. doi: 10.1155/2015/680749. Epub 2015 Feb 18. Review.

6.

The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.

Athanasakis E, Melloni E, Rigolin GM, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, Dal Monego S, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Dec 30;5(24):12635-45.

7.

The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway.

Agnoletto C, Brunelli L, Melloni E, Pastorelli R, Casciano F, Rimondi E, Rigolin GM, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2015 Feb 10;6(4):2385-96.

8.

Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model.

Tisato V, Garrovo C, Biffi S, Petrera F, Voltan R, Casciano F, Meroni G, Agnoletto C, Zauli G, Secchiero P.

PLoS One. 2014 Dec 15;9(12):e115387. doi: 10.1371/journal.pone.0115387. eCollection 2014.

9.

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.

Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM.

Oncotarget. 2014 Oct 30;5(20):10034-47.

10.

Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.

Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P.

Mol Cell Endocrinol. 2014 Aug 25;394(1-2):13-20. doi: 10.1016/j.mce.2014.06.004. Epub 2014 Jul 3.

PMID:
24998520
11.

Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.

Cervellati C, Secchiero P, Bonaccorsi G, Celeghini C, Zauli G.

Mediators Inflamm. 2014;2014:306848. doi: 10.1155/2014/306848. Epub 2014 May 21.

12.

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.

Agnoletto C, Melloni E, Casciano F, Rigolin GM, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Jun 30;5(12):4347-60.

13.

Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival.

Zauli G, Celeghini C, Monasta L, Martinelli M, Luppi S, Gonelli A, Grill V, Ricci G, Secchiero P.

Reproduction. 2014 Aug;148(2):191-8. doi: 10.1530/REP-14-0144. Epub 2014 May 13.

14.

In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure.

Voltan R, Zauli G, Rizzo P, Fucili A, Pannella M, Marci R, Tisato V, Ferrari R, Secchiero P.

Mediators Inflamm. 2014;2014:257081. doi: 10.1155/2014/257081. Epub 2014 Mar 23.

15.

Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction.

Tisato V, Zauli G, Gianesini S, Menegatti E, Brunelli L, Manfredini R, Zamboni P, Secchiero P.

J Immunol Res. 2014;2014:473765. doi: 10.1155/2014/473765. Epub 2014 Mar 25.

16.

The first trimester gravid serum regulates procalcitonin expression in human macrophages skewing their phenotype in vitro.

Rami D, La Bianca M, Agostinis C, Zauli G, Radillo O, Bulla R.

Mediators Inflamm. 2014;2014:248963. doi: 10.1155/2014/248963. Epub 2014 Mar 5.

17.

Inhibitory effect of natural anti-inflammatory compounds on cytokines released by chronic venous disease patient-derived endothelial cells.

Tisato V, Zauli G, Rimondi E, Gianesini S, Brunelli L, Menegatti E, Zamboni P, Secchiero P.

Mediators Inflamm. 2013;2013:423407. doi: 10.1155/2013/423407. Epub 2013 Dec 31.

18.

Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol.

Zauli G, Tisato V, Melloni E, Volpato S, Cervellati C, Bonaccorsi G, Radillo O, Marci R, Secchiero P.

J Clin Endocrinol Metab. 2014 Apr;99(4):E659-64. doi: 10.1210/jc.2013-4193. Epub 2014 Jan 21.

PMID:
24446659
19.

NF-κB pathways in hematological malignancies.

Gasparini C, Celeghini C, Monasta L, Zauli G.

Cell Mol Life Sci. 2014 Jun;71(11):2083-102. doi: 10.1007/s00018-013-1545-4. Epub 2014 Jan 14. Review.

PMID:
24419302
20.

Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders.

Campioni D, Voltan R, Tisato V, Zauli G.

Front Biosci (Landmark Ed). 2014 Jan 1;19:139-51. Review.

PMID:
24389177
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk